FDAsafety guidance66% confidence
Zydus Lifesciences Limited - 722576 - 06/02/2026
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (cardiology) as POKONZA; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Cardiology · Electrolyte Replacement
- Sub-indication
- Hypertension
Related signal: FDA Accepts Supplement for POKONZA by Genus Lifesciences